Theravance Biopharma Stock Alpha and Beta Analysis
| TBPH Stock | USD 9.61 0.36 3.61% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Theravance Biopharma. It also helps investors analyze the systematic and unsystematic risks associated with investing in Theravance Biopharma over a specified time horizon. Remember, high Theravance Biopharma's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Theravance Biopharma's market risk premium analysis include:
Beta 1.14 | Alpha 0.21 | Risk 2.09 | Sharpe Ratio 0.14 | Expected Return 0.28 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Theravance |
Theravance Biopharma Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Theravance Biopharma market risk premium is the additional return an investor will receive from holding Theravance Biopharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Theravance Biopharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Theravance Biopharma's performance over market.| α | 0.21 | β | 1.14 |
Theravance Biopharma expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Theravance Biopharma's Buy-and-hold return. Our buy-and-hold chart shows how Theravance Biopharma performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Theravance Biopharma Market Price Analysis
Market price analysis indicators help investors to evaluate how Theravance Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Theravance Biopharma shares will generate the highest return on investment. By understating and applying Theravance Biopharma stock market price indicators, traders can identify Theravance Biopharma position entry and exit signals to maximize returns.
Theravance Biopharma Return and Market Media
The median price of Theravance Biopharma for the period between Sat, Aug 24, 2024 and Fri, Nov 22, 2024 is 8.22 with a coefficient of variation of 5.9. The daily time series for the period is distributed with a sample standard deviation of 0.5, arithmetic mean of 8.42, and mean deviation of 0.39. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Theravance Bio Up 2.2 percent Since Last Earnings Report Can It Continue | 09/04/2024 |
2 | Theravance Biopharma Receives Buy Rating from HC Wainwright | 09/16/2024 |
3 | Theravance Biopharma, Inc. Receives 13.75 Consensus PT from Analysts | 10/02/2024 |
4 | Acquisition by Winningham Rick E of 3252 shares of Theravance Biopharma at 7.83 subject to Rule 16b-3 | 10/11/2024 |
5 | Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024 | 10/24/2024 |
6 | PTC Therapeutics Reports Q3 Loss, Tops Revenue Estimates | 11/07/2024 |
7 | Theravance Biopharma GAAP EPS of -0.26 misses by 0.03, revenue of 16.87M beats by 1.45M | 11/12/2024 |
8 | Theravance Biopharma Inc Q3 2024 Earnings Call Highlights Strong Sales Growth and ... | 11/13/2024 |
9 | Theravance Biopharma Third Quarter 2024 Earnings Revenues Beat Expectations, EPS Lags | 11/14/2024 |
10 | Insider Trading | 11/19/2024 |
11 | Theravance Biopharma to Present at Evercore HealthCONx Conference TBPH Stock News - StockTitan | 11/20/2024 |
About Theravance Biopharma Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Theravance or other stocks. Alpha measures the amount that position in Theravance Biopharma has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 (projected) | Payables Turnover | 2.35 | 4.24 | 26.65 | Days Of Inventory On Hand | 513.23 | 83.81 | 9.0E-6 |
Theravance Biopharma Upcoming Company Events
As portrayed in its financial statements, the presentation of Theravance Biopharma's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Theravance Biopharma's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Theravance Biopharma's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Theravance Biopharma. Please utilize our Beneish M Score to check the likelihood of Theravance Biopharma's management manipulating its earnings.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Theravance Biopharma
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Theravance Biopharma Backtesting, Theravance Biopharma Valuation, Theravance Biopharma Correlation, Theravance Biopharma Hype Analysis, Theravance Biopharma Volatility, Theravance Biopharma History and analyze Theravance Biopharma Performance. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Theravance Biopharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.